ArticleJournal of clinical laboratory analysis2026
Genotype-Driven Resolution of Panagglutination Over a Decade of Korean Rare Blood Program Case Archives.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAs populations age and chronic disease burden rises, transfusion demand grows in both volume and immunohematologic complexity. When reagent red blood cells (RBCs) in antibody screening and identification panels show uniform reactivity with a negative autocontrol and direct antiglobulin test, an alloantibody to a high-frequency antigen (HFA) is suspected. These cases pose persistent diagnostic challenges and may necessitate least-incompatible transfusions, potentially compromising safety. We evaluated whether a structured molecular approach within a national rare-blood program improves diagnostic resolution and transfusion planning in such cases.
methodsWe retrospectively reviewed suspected HFA alloantibody cases referred to the Korean Rare Blood Program (KRBP) case registry between 2013 and 2024. All cases underwent a two-tier molecular workflow consisting of allele-specific real-time PCR for targeted variants, followed by confirmatory Sanger sequencing when indicated. Clinical data, serology, genotyping results, and impact on transfusion management were abstracted and analyzed.
resultsOf 1031 referrals, 28 met inclusion criteria. Molecular testing identified underlying rare antigen-negative phenotypes in most cases, including Jr(a-) in 13/28 (46.4%) and Yk(a-) in 11/28 (39.3%) cases. The tiered genotyping strategy enabled accurate genotype-phenotype correlation and directly informed the selection of antigen-compatible RBC units and donor search strategies.
conclusionSuspected HFA alloantibodies frequently reflect clinically significant antigen deficiencies that cannot be resolved by serologic testing alone. Integration of a centralized molecular workflow with a national registry substantially improves diagnostic accuracy and transfusion safety. Expansion of family-based donor identification and systematic rare-phenotype surveillance is recommended to enhance national transfusion preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.